Informations générales (source: ClinicalTrials.gov)
Identification of Protein Markers of Epidemiological and Clinical Interest by MALDI-TOF (SPECTRASURV)
Observational
Assistance Publique Hopitaux De Marseille (Voir sur ClinicalTrials)
juillet 2018
juillet 2022
29 juin 2024
Not all infectious agents have the same epidemic potential, and this can vary widely
within the same species. Rapid determination of this potential is essential to optimize
control of infectious diseases. It is now accepted that identification with the species
is clearly insufficient to identify an epidemic and to carry out epidemiological
analyzes. Indeed, if the same bacterial species can present a great diversity of strains,
it is organized in clonal complexes having strong variations of clinical and
epidemiological expression.
More specifically, on a bio-epidemiological level, the clonal identification of the
bacterial agent is a real asset because it can make it possible to identify the highly
virulent strains or known to be resistant, the clones associated with nosocomial
infections, the source of the infection. an epidemic and to follow its spatio-temporal
extension, to know the epidemiological antiquity of the clone, to follow or rebuild a
chain of transmission, to discover epidemic clusters.
There are rapid identification techniques, for example by polymerase chain reaction
(PCR), but which are targeted at particular genomic compositions previously identified.
Routine bacterial identification now rests on the determination of the protein
composition by mass spectrometry (MALDI-TOF). The bacterial spectrum is compared to a
reference library of protein composition, thus obtaining an identification equivalent to
that based on the 16s RNA (ribonucleic acid 16s) and can descend to an infra-species
level.
The aim of this work is to use the proteome part of the MALDI-TOF spectrum to identify
peaks that signal clonality and to determine proteomic fingerprintings that can be used
for epidemiological and clinical purposes.
Instead of relying on expensive genomic methods, the identification of the clonal
characteristics of the strains will rely on the bacterial proteome present on the
MALDI-TOF spectrum that is produced during the routine identification of the bacterium.
The results are intended to feed a complementary knowledge base
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Assistance Publique Hôpitaux de Marseille - 13354 - Marseille - France | Hervé CHAUDET, PH | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- bacterial identification by Matrix Assisted Laser Desorption Ionisation - Time of
Flight (MALDI-TOF)
- bacterial identification by Matrix Assisted Laser Desorption Ionisation - Time of
Flight (MALDI-TOF)
- Unidentified strain or noisy spectrum